Charles River Laboratories International (CRL) EBIT (2009 - 2025)

Charles River Laboratories International (CRL) has reported EBIT for 17 consecutive years, with -$283.4 million the latest figure, recorded in Q4 2025.

• In Q4 2025, EBIT fell 69.03% year-over-year to -$283.4 million; the TTM figure through Dec 2025 stood at $25.2 million (down 88.93% YoY), while the FY2025 annual figure was $25.2 million, down 88.93% from the prior year.
• EBIT came in at -$283.4 million for Q4 2025 at Charles River Laboratories International, down from $133.8 million in the prior quarter.
• The five-year high for EBIT was $187.4 million in Q2 2022, with the low at -$283.4 million in Q4 2025.
• Average EBIT over 5 years is $105.5 million, with a median of $143.2 million recorded in 2021.
• Across the five-year window, EBIT soared 79.18% in 2021 and plunged 226.15% in 2024, its largest moves.
• Year by year, EBIT stood at $172.8 million in 2021, then fell by 5.21% to $163.8 million in 2022, then dropped by 18.86% to $132.9 million in 2023, then slumped by 226.15% to -$167.7 million in 2024, then plunged by 69.03% to -$283.4 million in 2025.
• According to Business Quant data, EBIT over the past three periods registered -$283.4 million, $133.8 million, and $100.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.